慢性心力衰竭器械治疗被引量：2

下载PDF

导出

摘要慢性心力衰竭（心衰）是一种复杂的临床症状群,为各种心脏病的严重阶段,严重影响患者的生活质量,且明显缩短患者寿命.美国2006年流行病学资料提示慢性心衰患者达570万[1],对我国10省市35 ～ 74岁城乡居民15 518人进行流行病学调查发现,慢性心衰患病率为0.9％,至少有420万心衰患者（2007年心衰指南）.基于β受体阻滞剂、血管紧张素转换酶抑制剂和醛固酮受体拮抗剂的“金三角”治疗给心衰患者带来益处,但是这些药物不能完全控制患者心衰的进展,慢性心衰的发病率和死亡率仍然在继续升高.近年来,在进一步研发新药的同时,医务工作者在慢性心衰的器械治疗领域进行了大量的探索,取得了长足的进步,成为慢性心衰治疗指南的一大亮点.心脏再同步化治疗（CRT）、埋藏式心脏复律除颤器（ICD）及心室辅助装置等慢性心衰器械治疗发展迅速,提高慢性心衰患者的心脏泵功能、改善症状、提高生活质量,甚至逆转心脏重构,减少心律失常致死的风险,进一步降低慢性心衰患者住院率及死亡率.

作者曾秋棠黎明张敏

机构地区华中科技大学同济医学院协和医院心内科

出处《临床内科杂志》 CAS 2015年第1期17-19,共3页 Journal of Clinical Internal Medicine

关键词心力衰竭慢性治疗器械

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献18

1Lloyd-Jones D,Adams R, Carnethon M, et al. Heart disease and stroke statistics 2009 update:a report from the American Heart Associa- tion Statistics Committee and Stroke Statistics Subcommittee[ J ]. Circu- lation ,2009,119 ( 3 ) :481-486.
2Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resyn- chronization on morbidity and mortality in heart failure [ J ]. N Engl J Med,2005,352 ( 15 ) : 1539-1549.
3Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventrieular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COM- PANION Clinical Investigators [ J ]. J Card Fail,2000,6 ( 3 ) :276-285.
4Moss A J, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events[ J]. N Engl J Med,2009,361 (14) : 1329-1338.
5Daubert C, Gold MR, Abraham WT, et al. Prevention of disease progres- sion by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction : insights from the Eu- ropean cohort of the REVERSE ( Resynchronization Reverses Remode- ling in Systolic Left Ventricular Dysfunction) trial[ J]. J Am Coll Car- diol, 2009,54 ( 20 ) : 1837 -1846.
6Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure[ J ]. N Engl J Med,2010,363 (25) : 2385-2395.
7Yancy CW,Jessup M,Bozkurt B,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Prac- tice Guidelines[J]. J Am Coil Cardiol,2013,62(16) :e147-239.
8John R, Kamdar F, Liao K, et al. Improved survival and decreasing inci- dence of adverse events with the HeartMate II left ventrieular assist de- vice as bridge-to-transplant therapy [ J ]. Ann Thorac Surg, 2008,86 (4) : 1227-1234 ".discussion 1234-1235.
9Ammirati E, Oliva F, Cannata A, et al. Current indications for heart transplantation and left ventricular assist device: a practical point of view [ J 1. Eur J Intern Med,2014,25 (5) :422-429.
10Floras JS. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure [ J ].I Am Coil Cardiol, 1993,22 ( 4Suppl A) :72A-84A.